The role of elotuzumab in the treatment of multiple myeloma
Prof. MUDr. Ivan Špička, CSc.
I. interní klinika - klinika hematologie 1. LF UK a VFN, Praha
Therapy of multiple myeloma has substantially changed during last two decades due to new generation biological drugs proteasome inhibitors, immunomodulators and monoclonal antibodies. Elotuzumab is first in class monoclonal antibody approved for clinical use by Food and Drug Administration as „breakthrough therapy". Its target antigen is surface receptor SLAMF7 (or CS1) from CD2 group and SLAMF (signaling lymphocytic activation molecule) family. At present elotuzumab is approved for relapsed myeloma patients in combination with dexamethasone and either lenalidomide or pomalidomide.
multiple myeloma, monoclonal antibodies, elotuzumab, lenalidomide, pomalidomide
The full article is only available to subscribers
Become a regular subscriber to our Oncological Review...